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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.026Emerging evidence suggests that cancer branched evolution may affect biomarker validation, clinical
outcome, and emergence of drug resistance. The changing spatial and temporal nature of cancer
subclonal architecture during the disease course suggests the need for longitudinal prospective studies
of cancer evolution and robust and clinically implementable pathologic deﬁnitions of intratumor
heterogeneity, genetic diversity, and chromosomal instability. Furthermore, subclonal heterogeneous
events in tumors may evade detection through conventional biomarker strategies and inﬂuence clinical
outcome. Minimally invasive methods for the study of cancer evolution and new approaches to clinical
study design, incorporating understanding of the dynamics of tumor clonal architectures through
treatment and during acquisition of drug resistance, have been suggested as important areas for
development. Coordinated efforts will be required by the scientiﬁc and clinical trial communities to
adapt to the challenges of detecting infrequently occurring somatic events that may inﬂuence clinical
outcome and to understand the dynamics of cancer evolution and the waxing and waning of tumor sub-
clones over time in advanced metastatic epithelial malignancies. (Am J Pathol 2013, 182: 1962e1971;
http://dx.doi.org/10.1016/j.ajpath.2013.02.026)Intratumor heterogeneity (ITH) occurs at multiple genetic,
phenotypic, and functional levels, with tumor diversity
commonly observed in cellular morphology, gene expres-
sion, motility,1 proliferation,2 immunogenic and angiogenic
potential, tumorigenicity,3 resistance to treatment,4 and abi-
lity to metastasize.5
Tumor morphologic heterogeneity has long been recog-
nized by pathologists; indeed,Virchow, often referred to as the
father ofmodern pathology, observed pleomorphismof cancer
cells within tumors in the nineteenth century,6,7 forming the
basis of many contemporary tumor grading prognostic clas-
siﬁcation systems.8 ITH is also considered in tumor immu-
nohistochemical quantitative analyses that consider both the
intensity of cellular staining and the percentage of tumor cells
scoring positive for the immunohistochemical marker.
Despite common histopathologic observations of ITH in the
clinical and pathologic settings, our knowledge of the extent of
diversity and the potential association of ITH with common
histopathologic variables, as well as the underlying mecha-
nisms that maintain and promote diversity, remains relativelystigative Pathology.
.rudimentary. An unmet challenge is to integrate common
clinicopathologic observations that inform current risk strati-
ﬁcation models with genetic and epigenetic analyses of tumor
heterogeneity to address how tumor subclonal diversity is
mediated, decipher its changing nature through the disease
course, and determine its potential relevance to therapeutic
resistance and clinical outcome. Understanding how tumors
adapt through therapy and at relapse may shed light on ther-
apeutic resistancemechanisms. In this review,we consider the
historical evidence supporting tumor subclonal evolution and
suggest that adapting cancer clinical trial infrastructure to the
challenges of subclonal tumor diversity and its changing
nature over space and time may enhance our understanding of
drug response and therapeutic failure.
Historical Perspective on Cancer Evolution and
Heterogeneity
Darwin, in his seminal work, On the Origin Of Species, ﬁrst
postulated that heritable phenotypic variation underlies
Clinical Paradigms of Cancer Evolutionnatural selection and is responsible for adaptation and emer-
gence of new species. Although initially used to describe how
organisms evolve across generational time, the idea that evo-
lutionary forces also drive tumor development has now been
documented extensively.9e11 For more than a century, the
multiplicity of chromosomal aberrations associated with
abnormal cellular morphology in many tumors has been
documented by pathologists and has continued to serve as
a means of identifying malignant cells and to stratify the
malignant potential of certain cancers.12 As early as 1902,
Theodor Boveri proposed aneuploidy as a cause of tumori-
genesis. This was based on von Hansemann’s observations in
1890 of asymmetric mitoses in epithelial cancers and on
Boveri’s evidence that aneuploidy leads to abnormal devel-
opment and lethality in developing sea urchin embryos.13,14
More than half a century later, a clonal evolutionary model
of tumor progression was postulated in which observed
cytogenetic changes and acquired genetic variability provide
a substrate for environmental selection, leading to a compel-
ling framework for understanding cancer progres-
sion.9,10,15,16 In 1976, Nowell10 articulated the concept of
darwinian evolution in cancer, proposing that genetic insta-
bility generates heterogeneity in cancer cells and that these
heterogeneous populations are then subject to evolutionary
forces and the pressures of natural selection. Presciently,
Nowell stated in his article that “more research should be
directed toward understanding and controlling the evolu-
tionary process in tumors before it reaches the late stage
usually seen in clinical cancer.”10,pp23 Therefore, in the
context of tumor evolution, it has been argued that genetic
heterogeneity is not merely a feature of cancer but is the fuel
through which the selection process is driven.
A key principle in the modern synthesis of evolutionary
theory is Dobzhansky’s17molecular deﬁnition of evolution as
the change in an allele’s frequency within a population. This
fundamental description of evolution connects the observa-
tions of evolutionary selection with the concept of population
heterogeneity at the genotypic level. The understanding of
cancer progression in terms of evolutionary and population
processes has been revisited through the years (recent
reviews18e20), perhaps reﬂecting Dobzhansky’s emphatic
assertion in 1973 that “nothing in biologymakes sense except
in the light of evolution.”21
According to this evolutionary model of cancer, genetic
drift and natural selection drive the diversity and progression
of tumors, and indeed, most tumors show a striking degree of
heterogeneity in measurable traits such as cellular mor-
phology,22,23 and expression of cellular markers.24,25
Subsequent studies leveraged karyotypic analyses of chro-
mosomes and ﬂuorescence in situ hybridization (FISH) to
show that substantial genetic heterogeneity can exist in tumor
cells.26e30 Teixeira et al26 also observed that increased
genomic imbalances in primary breast cancers correlatedwith
the presence of lymph node metastases. Other studies have
examined the relationship between heterogeneity in ductal
carcinoma in situ and the propensity for development ofThe American Journal of Pathology - ajp.amjpathol.orginvasive ductal carcinomas. Intratumor heterogeneity of
microsatellite marker allelic loss seemed to be relatively
higher in ductal carcinoma in situ associated with invasive
lesions than in pure ductal carcinoma in situ samples with no
invasive disease, which suggests that ITH may have a role in
the genetic divergence required for evolutionary robustness
during disease progression.31,32 Alluding to work that is still
ongoing, Heppner1 proposed in 1984 that understanding the
forces and factors that generate ITH in populations of tumor
cells will shape clinical treatments and therapy strategies.
Indices of Intratumor Heterogeneity and Clonal
Diversity
Genotypic and phenotypic diversity may provide important
risk stratiﬁcation measures. In an elegant study by Maley
et al,33 high clonal diversity in preinvasive Barrett’s esoph-
agus was found to be a predictor of progression to esophageal
adenocarcinoma. Diversity was measured as the number of
distinct clones of cells within the specimen. Clones were
identiﬁed by differences inﬂowcytometricDNAcontent, loss
of heterozygosity, microsatellite shifts (new alleles), muta-
tion, methylation, and copy number variation measured
via FISH. Using these various measures of genetic diversity,
the number of distinct clones in each tumor was then esti-
mated, and the Shannon index was calculated. The Shannon
diversity index expresses observed genetic diversity as
a numerical value applied from diversity measures from
ecology and evolution sciences.34,35 Various measures of
tumor population diversity have been investigated by several
groups,33,36e38 with different indices reﬂecting the number of
clones or allelic diversity in a sample. Although there are
substantial differences in methods, the studies of different
cancer types and models have shown that high levels of
heterogeneity and genetic diversity may have important
clinical implications as a biomarker of risk stratiﬁcation and
could provide prognostic and predictive value for increased
tumorigenicity, therapeutic resistance, and poor clinical
outcome. Work by us and others has demonstrated that
genotypic diversity and chromosomal instability (CIN)39 is
associated not only with intrinsic multiple-drug resistance but
also with lowered disease-free and overall survival in colo-
rectal cancer.4,40,41
Unraveling Intratumor Heterogeneity through
Deep Sequencing
More recently, sequencing efforts have highlighted the
extent of diversity mediated by branched cancer clonal
evolution. Several salient studies have highlighted this.
Shah et al42 described the genome of a metastatic lobular
breast tumor with 19 nonsynonymous mutations present in
the metastasis that were not present in the primary tumor
diagnosed 9 years previously, illustrating the temporal
dynamics of ITH.1963
Murugaesu et alUsing FISH-based techniques, Anderson et al43 deﬁned
genetically distinct subclones of acute lymphoblastic leu-
kemia and deduced the likely complex evolutionary dynamics
and resulting clonal architecture and convergent evolution in
different subclones in the same patient. Navin et al27,44 have
described profound intratumoral heterogeneity within indi-
vidual breast tumors showing multiple intermixed karyotypic
tumor populations that differ by major structural chromo-
somal gene ampliﬁcations.
Yachida et al45 demonstrated heterogeneity in pancreatic
cancer by whole-exome sequencing and copy number anal-
ysis of samples obtained from different anatomical regions of
a pancreatic cancer and showed that clonal tumor populations
present in the primary tumors give rise tometastatic disease in
a branched evolutionary pattern, with progressor mutations
common to metastatic sites and within regionally separated
subclones of the primary lesion. Campbell et al46 demon-
strated a model in which clonal evolution, driven by genome
instability, underlies the development ofmetastatic pancreatic
cancer and phylogenetic trees across metastases show organ-
speciﬁc branches. These studies and work from our group
provide support for branched cancer clonal evolution with
predicted convergent and divergent evolution.43,45e48
With advances in sequencing technology and bio-
informatics algorithms, tumor phylogenetic trees of clones
derived from multiple-region sequencing analyses can be
constructed in greater detail. Invaluable information as to
how the cancer has evolved and the sequence of somatic
mutation events that occurred during tumor evolution can be
derived from the tree structure. When combined with ploidy
and allelic imbalance analyses, these techniques can begin to
illuminate the sequence of somatic events that might con-
tribute to the onset of tumor genomic instability. We hypo-
thesize that the changing nature of the branched tree structure
may also enable relationships between subclonal populations
and resistance to treatment to be deciphered over time
(Figure 1). Work from our group indicates that despite
extensive ITH in renal tumors, convergent evolution occurs
whereby different mutations in the same driver gene or ge-
netic aberrations converging on the same pathway occur in
spatially separated regions of the tumor (separate clades of
the phylogenetic tree).48 Genetic events subject to evolu-
tionary convergence suggest routes required for tumor pro-
gression or maintenance that may be predictable, providing
opportunities for therapeutic exploitation.
Recent studies in multiple myeloma49e51 and acute
myeloid leukemia52 show the complexity of the evolutionary
process and the dynamics of clonal evolution over time.
Sequential sequencing through different lines of therapy at
progression highlights the effects of DNA damaging agents
(alkylating drugs), leading to expansion of resistance clones
that either existed before the onset of treatment or formed as
a result of new genomic alterations gained during therapy. In
a study by Keats et al,51 the enhanced complexity of the
relapsed subclone suggests that treatment with DNA damag-
ing agents may potentially exacerbate genomic complexity.1964Similarly, in a study by Schuh et al,53 whole-genome
sequencing was used to track subclonal heterogeneity in
three patients with chronic lymphocytic leukemia who had
undergone repeated cycles of therapy. They show that
heterogeneous cell populations are subject to darwinian
selection and may respond differentially to treatment. These
studies highlight the clinical need to monitor changes in the
subclonal composition of cancers during disease progression
and the iatrogenic effect of therapy on tumor diversity.
With increasing evidence for the extent and ﬂux of ITH
during the disease course, the next challenge will be to
address the implications of tumor diversity for diagnostic
and biomarker strategies and the effect of ITH on treatment
efﬁcacy and clinical outcome. Identiﬁcation of tractable
therapeutic targets that may limit the onset and propagation
of tumor heterogeneity may be a key step in this process.Spatial and Temporal Heterogeneity and
Implications for Biomarker Validation and
Targeted Therapeutics
ITH poses a challenge for personalized cancer diagnosis and
treatment resistance. Spatial heterogeneity in glioblastoma
has been observed in which mesenchymal-epithelial transi-
tion factor, platelet-derived growth factor receptor-a, and
epidermal growth factor receptor (EGFR) receptor tyrosine
kinases are ampliﬁed and expressed simultaneously in adja-
cent intermingled cells in a mutually exclusive manner.54
This heterogeneity has also been demonstrated to have
functional consequences, as shown in a study by Szerlip
et al55 in which cell lines grown from the same glioblastoma
with heterogeneous platelet-derived growth factor receptor-a
or EGFR ampliﬁcation states require both platelet-derived
growth factor receptor-a and EGFR inhibition for maximal
PI3K pathway attenuation and growth inhibition.55 Our group
has shown that individual tumors in renal carcinomas
exhibited extensive spatial ITH.48 For example, 63% to 69%
of the total somatic mutational burden, identiﬁed through
multiple-region sequencing of two primary and metastatic
renal cancers, was not detectable in every tumor region,
several tumor suppressor genes showed multiple distinct and
spatially separated inactivating mutations within a single
tumor, and gene expression signatures of good and poor
prognosis were detected in different regions of the same
tumor.
A number of studies also show evidence of temporal
heterogeneity. PIK3CA mutations may be discordant
between primary and corresponding metastatic disease in
breast cancer,56 TP53 mutation frequency increased steadily
from 8% of adenomas to 53% of metastases in colorectal
cancers,57 and the discordance rate was 13.9% between
matched samples in EGFR mutant lung adenocarcinomas,58
emphasizing that the treatment of metastatic disease
according to the biomarker expressed in the primary tumor
may not always be optimal. This temporal evolution ofajp.amjpathol.org - The American Journal of Pathology
Figure 1 Cancer branched evolution. A:
Ubiquitous mutation in the tumor (mutation A)
found in every subclone and every tumor region,
represented in the trunk and branches of the tree.
Diverse heterogeneous somatic events are repre-
sented by the branches and the leaves (mutations
B, C, T790M, and EeK). B: Schema of tumor
dynamics and evolution through targeted therapy
and drug resistance. Heterogeneous drug-resistant
mutation T790M is present in the tumor at low
frequency and may even evade detection because
of sampling bias. Enrichment of heterogeneous
drug-resistant mutation T790M through therapy.
Clinical Paradigms of Cancer Evolutioncancer has perhaps been best examined in breast cancer with
receptor conversion of estrogen receptor, progesterone
receptor, and human epidermal growth factor receptor 2 in
distant breast cancer metastases, demonstrated in a sub-
stantial percentage of patients. Conversion for estrogen
receptor-a and progesterone receptor was mainly from posi-
tive to negative, whereas human EGFR-2 conversion occurred
in both directions.59 Such receptor conversion could result,
not only in withholding effective treatment from patients but
could also result in ineffective administration of agents.60
Spatial and temporal genetic heterogeneity may contribute
to some of the difﬁculties in validating and qualifying
biomarkers for clinical implementation despite the continued
discovery of potential novel biomarkers.61 Indeed, a single
drug may be inadequate to treat a genetically heterogeneous
tumor because clones occurring with low frequency, not
readily detectable at diagnosis, may contribute to therapeutic
failure and poor outcome. Biomarker efforts must adapt to the
challenges of identifying low-frequency events present in
tumors before therapy that may ultimately inﬂuence
outcome. Complex combination therapeutic approaches may
be required (with the appropriate regulatory caveats of drug
combination approaches) to delay acquisition of drug
resistance.Low-Frequency Subclonal Tumor Somatic Events
May Inﬂuence Outcome
It is conceivable that biomarkers that have proved successful
likely occur in the early stages of tumor development and are
ubiquitous events occurring at all sites of disease (trunk
somatic aberrations).62 For example, somatic mutations in
VHL (clear cell renal cell carcinoma)48 or p53 (triple-negative
breast cancer)63 and RAS, BRAF, and PIK3CA mutational
status (colorectal cancer)57 seem to have the hallmarks of
such early driver events and clonal dominance, mapping toThe American Journal of Pathology - ajp.amjpathol.orgthe trunk of the tumor phylogenetic tree. The next step is to
understand the highly dynamic evolutionary processes in
individual tumors to identify both the clonal driver mutations
present ubiquitously in the trunk of the phylogenetic tree and
the potential existence of subclonal driver mutations present
in the branches, which may also affect outcome and treat-
ment resistance (Figure 1). After identiﬁcation of complex
branching architecture of tumors,43e45,47,48 the next chal-
lenge is to adapt clinical trial infrastructures to address op-
timal therapeutic approaches in treating such heterogeneous
solid tumors.
Although targeting speciﬁc mutations within a tumor may
be the favored approach to treatment of certain cancers, in
advanced disease, this inevitably selects for resistant clones.
Where studied, it seems that these resistant cells may already
exist in the primary tumor at diagnosis, as has been shown in
acute lymphoblastic leukemia64,65 and chronic myeloid
leukemia,66 but can go undetected because of the limited
sensitivity of the methods used. More recently, a number of
studies using sensitive diagnostic techniques have shown that
the ﬁnal subclone that may inﬂuence therapeutic and clinical
outcome may be present at very low frequency at diagnosis
and that dynamic changes in the subclonal architecture of the
tumor may change and compete with each other for domi-
nance during the disease course and through different lines of
treatment. Such a phenomenon has been observed using
FISH-based techniques in multiple myeloma when the clone
that ultimately determined outcome after ﬁve lines of therapy
was present at 1% of the clonal frequency of the diagnostic
bone marrow aspirate.51 Similarly, in EGFR-driven none
small cell lung carcinomas (NSCLCs), the observation of
low-frequency c-MET ampliﬁcation or the T790M gate-
keeper mutation that may be present as a subclonal fraction in
EGFR mutant tumors before treatment were associated with
acquired resistance toEGFR inhibitors and reducedprogression-
free survival and were enriched during treatment pro-
gression.67e69 Evidence also suggests that some EGFR1965
Murugaesu et altyrosine kinase inhibitor-resistant tumors show different
mechanisms of resistance at different sites of disease.58
Others may have undergone transformation to small cell
lung cancer (SCLC) and are sensitive to standard SCLC
treatments, justifying the need to re-examine tumor histology
longitudinally in NSCLC.67 Similarly, this has also been
described for NSCLC, with EML4-ALK translocations
showing heterogeneity ofALK resistancemutations, such that
the anaplastic lymphoma kinase domain can developmultiple
distinct mutations that can abrogate the capacity of crizotinib
to inhibit anaplastic lymphoma kinase within the same
tumor.70,71
It is clear that therapy can select for the expansion of rare
clones35,72 and that low-frequency clones can determine
outcome. Longitudinal prospective observational studies
will address whether more heterogeneous tumors are more
likely to harbor one of these resistance mutations, the rele-
vance of underlying genetic factors that determine whether
subclones recede or expand, and whether detection of sub-
clonal somatic events in advance of therapy can forecast the
composition of the relapsing tumor. Ultimately, biomarker
strategies will have to adapt to address these questions.Developing Indices of Tumor Heterogeneity
Mathematical models that incorporate measures of genetic
diversity and selection pressures (from therapies) to predict
emergence of therapy resistance73e75 need to be evaluated
clinically. Questions remain as to which measurements
(histopathologic, epigenetic, transcriptomic, or proteomic)
to include in indices of diversity. The optimal approach to
compilation of such an index likely lies in prospective
clinical studies that systematically investigate the measur-
able heterogeneity for each cancer, integrated with clinical
and therapeutic outcome data. This may enable relationships
between diversity and clinical outcome to be prospectively
investigated and ultimately to express the observed genetic
diversity as a numerical value that might be implementable
clinically.
Another consideration is the extent of ITH and how this
may affect outcome. Low levels of genetic heterogeneity
have been linked to population extinction susceptibility in
experimental models76,77 because a population with low
diversity would have less potential for coping with new
environmental selection pressures. Conversely, extremely
high mutation rates could lead to reduced ﬁtness due to
decreased ﬁdelity in the transmission of a functional genome.
Application of lethal mutagenesis by elevating the mutation
rate with mutagens has been demonstrated in RNA viruses,78
although RNA viruses have mutation rates several orders of
magnitude higher than organisms with DNA-based genomes.
An accurate means of assaying the mutation rate in tumor
populations could potentially be exploitable and therapeuti-
cally tractable. Indeed, some studies suggest the intolerance
of excessive CIN in carcinomas,79 and it has been proposed1966that there may be an optimal level of CIN for tumor
progression80 beyond which further instability provides no
growth advantage and may even be deleterious for cancer cell
survival,81 analogous to mutational meltdown in bacteria82 or
error catastrophe in viruses.83 This may have prognostic and
therapeutic implications in certain cancers.84
There is also increasing evidence for CIN and the diver-
gent evolution of metastatic tumor cells. Identiﬁcation of
organ-speciﬁc branches within phylogenetic trees in meta-
static studies is indicative of environmental factors that select
for speciﬁc genomic changes.45,46 Our work in renal cancer
highlighted that a single region of the primary tumor
demonstrated tetraploidy that was most closely related to the
metastatic sites that were chromosomally unstable,48 sug-
gesting that tetraploidy provided a genetic background
permissive for the development of CIN, as seen in animal
models.85 Stratton and Campbell’s group86,87 have provided
further evidence of branched tumor growth with in-depth
whole genome sequencing analysis of 21 breast cancers.
They also showed that chromosomal instability is not usually
the earliest source of heterogeneity in breast cancer evolution
but may be an ongoing process in intermediate and later
evolutionary time points of the disease.86,87Evolution and the Ecological Microenvironment:
New Clinical Trial Paradigms
In considering not only the selection processes that shape
tumor clonal life histories but also the ecological interactions
between tumor clones and the surrounding tissue microen-
vironment,11 Maley et al88 proposed that clonal heteroge-
neity could potentially be exploited for therapeutic beneﬁt. In
theory, boosting the selective advantage of relatively benign
clones might be used to drive malignant clones to extinction.
In addition, the selective advantage of clones sensitive to
a particular therapy can be boosted, enabling them to achieve
clonal dominance, and then treatment can be applied. In silico
modeling suggests that these strategies can be more efﬁcient
than standard cytotoxic therapies.88 Although conceptually
attractive, these strategies have not been tested in the clinic or
in vivomodels; furthermore, we lack the ability to selectively
single out and boost benign or chemosensitive clones.
Gatenby et al89 followed the logical progression of such
a perspective and showed that, rather than administering
a single potent therapeutic regimen that selects for resis-
tance, a population control approach through continual
changes in the selection and ﬁtness landscape can result in
lowered continuous tumor burden in an animal xenograft
model. In this adaptive therapy model, mice were subcuta-
neously injected with an ovarian cancer cell line, and the
resulting tumor was treated with either three high dosages of
carboplatin to mimic standard therapy or with multiple
dosages of carboplatin that are adaptively lowered when
growth of the tumor is attenuated. Animals treated long
term with multiple dosages of carboplatin showed reducedajp.amjpathol.org - The American Journal of Pathology
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advanced cancer is to treat tumors with the maximum tol-
erated dosage of drugs, with the objective of killing the
largest possible fraction of tumor, which primarily kills
chemosensitive cells. However, this strategy would be
expected to fail if resistant clones already exist before the
start of treatment because this creates a powerful selective
pressure that will inevitably beneﬁt clones that have intrinsic
resistance to the treatment.
The objective of adaptive therapy as proposed by Gatenby
et al89 is to keep tumor size at bay by adjusting drug dosage
and timing of drug administration on the basis of tumor
response. This strategy may prevent resistant variants from
becoming clonally dominant by maintaining therapy-
sensitive variants in the population. One approach would
be to cycle treatments on and off, analogous to metronomic
dosing strategies with the goal of targeting the stroma or
endothelium, with the objective of sustaining a chemosen-
sitive population to oppose the outgrowth of chemoresistant
clones. This type of treatment would cause periods of growth
and shrinkage and would, in theory, control tumor burden but
without the goal of complete eradication of the disease. This
approach is being evaluated in locally advanced and/or
metastatic renal cancer to evaluate the use of a modiﬁed
sunitinib schedule (with treatment breaks until progression
and recommencement of sunitinib therapy) compared with
the standard sunitinib schedule (International Standard
Randomised Controlled Trial Number Register, http://
www.controlled-trials.com/ISRCTN06473203, last accessed
December 12, 2012).Clinical Study Design to Assess the Spatial and
Temporal Dynamics in Cancer Clonal Evolution
If a tumor contains multiple subclones that may be spatially
separated, how can the subclone that has the dominant effect
insofar as therapeutic outcome be identiﬁed? Furthermore, it
would be logical to propose that more heterogeneous cancers
are more likely to harbor one of these resistance mutations;
however, this has yet to be demonstrated. The cell pop-
ulations within a tumor continuously evolve, posing a major
challenge for effective cancer treatment separated spatially
within the patient. To understand the clinical behavior and
evolution of tumors, it may be beneﬁcial to study both the
spatial and temporal dynamics of cancer evolution in
a prospective observational cohort study90 (Figure 2).
Because of the evolution of cancer over time, oncology
units are increasingly adopting strategies to perform repeat
biopsy of sites of metastases on disease progression as
standard of care. Prospective observational clinical studies
may enable the evolutionary mutational landscape of cancers
to be studied to increase our understanding of the dynamics
of genetic instability and ITH over time in combination with
detailed clinical and histopathologic annotation for each
patient. Such studies will help to decipher the frequency ofThe American Journal of Pathology - ajp.amjpathol.orgbranched evolutionary growth in cancers and improve our
understanding of when in the metastatic process distinct
somatic events and the initiation of genomic instability are
acquired. Ultimately, the effect of ITH on clinical outcome
can be identiﬁed by deciphering tumor evolution on a patient-
by-patient basis to develop a better understanding of the
genetic events that contribute to drug resistance and the
potential capacity of adjuvant therapies to exacerbate
genomic instability. Characterizing ITH via sequential tumor
biopsies and blood-based analyses of tumor DNA over time
will help to help the evolutionary dynamics of somatic
mutational heterogeneity and chromosomal structural and
numerical instability present in the primary tumor, lymph
nodes, and distant metastases during the disease course.
Through the mapping of tumor growth in greater detail and
reconstructing evolutionary histories of individual tumors,
mechanisms that contribute to genetic diversity may be
identiﬁed. Subsequently, key genetic events implicated in the
initiation of metastasis and drug resistance may be deci-
phered. Accumulation of such prospectively collected and
combined clinicogenomics data may help guide strategies for
future trials addressing the changing subclonal architecture of
the tumor.Dynamics of Tumor Subclonal Architecture and
Pruning of Phylogenetic Branches through
Therapy
Phenotypic heterogeneity in drug sensitivity proﬁles that may
be spatially separated or present at low frequency in minor
subclones of the tumor suggests that proﬁling cancer cell
phenotypes from single biopsy samples to guide therapeutic
decision making from heterogeneous tumors may prove
challenging. This underscores the importance of repeat tumor
sampling in light of spatial and temporal tumor evolution.
This is illustrated in Figure 1, which demonstrates the
changing clonal architecture of a tumor throughout treatment.
It is often impractical to obtain biopsy samples from
some anatomical locations or from multiple metastatic sites;
thus, the predictive value of biomarkers assessed in the
initial diagnostic specimens has been critical in the clinical
decision-making process.91 Academic-led prospective
studies will help to predict the clonally dominant drivers
and establish whether analysis of circulating tumor DNA
(ctDNA) can be used to predict early relapse and track
tumor subclonal evolution during treatment, acquisition of
drug resistance, and disease progression. That somatic
evolution may differ between metastatic sites in an
individual patient44,45 suggests that genomic proﬁling of
biopsy material from a single metastatic lesion may not be
sufﬁcient to completely capture the genomic diversity of
advanced solid cancers. Recent advances in whole genome
sequencing of ctDNA highlights the potential of using
ctDNA to provide a broader picture of clonal evolution
of tumors during progression.92 Looking for diagnostic1967
Figure 2 Schema of an integrated clinical approach to understanding the effect of intratumor heterogeneity on disease progression and clinical outcome.
The blue box outlines the clinical tracking, interventions, and sampling of materials in a patient. The green box outlines the histopathologic analyses to
examine the extent of heterogeneity at the cytologic and histologic levels in multiple sectors of each tumor biopsy sample. FACS, ﬂuorescence-activated cell
sorting; IHC, immunohistochemistry. The purple box indicates known gene drivers that could be validated at two separate points in real time in a Good Clinical
Laboratory Practice laboratory (GCLP lab) to stratify patients into early-phase adaptive trials. The red box describes assessment of ITH at the molecular level by
sequencing, and the gray box highlights an area for technology development with the use of ctDNA as a means of tracking tumor evolution.
Murugaesu et alanswers in ctDNA is a challenge, with limits to the sensi-
tivity of detection, in particular in patients with less
advanced disease. However, this technology still needs to be
developed and validated, as it is likely to be a more practical
and safe method to track cancer evolution throughout
therapy when multiple repeat biopsies are not feasible.
In the long term, these approaches may help develop
clinical and scientiﬁc genomics platforms for data collection
but will require international collaboration of large cancer
centers within different health care systems so that the data
tracking cancer evolution from primary to metastatic tumors
is publicly available to the medical and scientiﬁc commu-
nity for implementation. Validation of key driver mutations,
occurring as early founder events in the tumor phylogenetic
trunk, may further guide stratiﬁcation of cancer treatment
and future clinical trial inclusion.Conclusion
The issues discussed herein underscore the importance of
obtaining a more detailed understanding of the origin and1968temporal evolution of cancer. However, large-scale collab-
orative efforts will be required to integrate regional and
temporal tumor sampling of primary and metastatic tumors
through lines of therapy, incorporating next-generation
sequencing into the clinic in real time and to then evaluate
this genomic information at routine tumor board review.
Companion diagnostics, deﬁning actionable events that
consider clonal dominance, may also be required in clini-
cally certiﬁed laboratories to ensure that clinical decisions
can be made in real time. This will provide a number of
logistic and practical challenges and will involve coordi-
nation with a number of different disciplines to efﬁciently
interpret and validate the data and to then successfully use
these data for subsequent adaptive or combination thera-
peutic trials. Longitudinal observational trials will be para-
mount to decipher the evolution of individual cancers and
increase our understanding of the biologic features of the
underlying disease. This may inform a paradigm for cancer
management based on evolutionary principles that may lead
to an enhanced understanding of the drivers of tumor
heterogeneity, adaptation, and the capacity to acquire drug
resistance.ajp.amjpathol.org - The American Journal of Pathology
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